Rockefeller Capital Management L.P. Grows Stock Position in Amgen Inc. (NASDAQ:AMGN)

Rockefeller Capital Management L.P. grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 452,590 shares of the medical research company’s stock after purchasing an additional 4,901 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.08% of Amgen worth $145,800,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AMGN. Capital Performance Advisors LLP bought a new stake in shares of Amgen in the 3rd quarter worth about $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen in the second quarter worth about $26,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the second quarter valued at about $30,000. nVerses Capital LLC acquired a new stake in Amgen during the second quarter valued at approximately $31,000. Finally, Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter worth approximately $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $380.00 price target on shares of Amgen in a research report on Wednesday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective on shares of Amgen in a research report on Tuesday, November 12th. Wolfe Research initiated coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Finally, Bank of America boosted their price target on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $323.05.

Amgen Stock Up 0.0 %

NASDAQ:AMGN opened at $280.07 on Friday. Amgen Inc. has a 1-year low of $257.80 and a 1-year high of $346.85. The firm has a market capitalization of $150.55 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 2.62 and a beta of 0.60. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The business’s fifty day moving average price is $312.46 and its 200 day moving average price is $317.31.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.96 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 19.52 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.